Medplus Health Services Ltd

Medplus Health Services Ltd has announced that its Board of Directors will convene on July 21, 2026. The primary agenda item is to consider and approve the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The results will be submitted to the stock exchanges post-meeting and published in newspapers. Additionally, the trading window for designated persons will be closed from July 1, 2026, to July 23, 2026, in compliance with SEBI's insider trading regulations.

Medplus Health Services Ltd announced that its subsidiary, Optival Health Solutions Private Limited, has received a suspension order for a Drug License for a store located in Nashik, Maharashtra. The suspension is for a period of five days, effective from July 4, 2026. This action is based on alleged violations of Rule 65 of the Drugs and Cosmetics Act, 1940, and Drugs and Cosmetics Rules, 1945. The company estimates a potential revenue loss of ₹0.75 lacs due to this suspension. The details of the order will be available on the company's website and stock exchange websites.

Medplus Health Services Ltd's subsidiary, Optival Health Solutions Private Limited, has received a suspension order for a drug license for a store located in Subramanyanagar, Rajajinagar, Bangalore. The suspension is for a period of three days, effective from July 1, 2026. This action was taken by the Assistant Director, Drugs Control Administration, Bangalore Circle-1, under Rule 65 of the Drugs and Cosmetics Act, 1940, and Rules, 1945. The company anticipates a potential revenue loss of approximately ₹5.13 lacs due to this suspension. The details of the order will be made available on the company's website and stock exchange websites.

Medplus Health Services Ltd announced that its subsidiary, Optival Health Solutions Private Limited, has received a suspension order for the drug license of a store located in Davanagere, Karnataka. The suspension is for two days, from June 30, 2026, and is due to alleged violations under the Drugs and Cosmetics Act, 1940. The company estimates a potential revenue loss of Rs 0.80 lacs as a result of this temporary suspension. The details of the order are available on the company's website and stock exchange websites.

Medplus Health Services Ltd announced that its subsidiary, Optival Health Solutions Private Limited, has received two suspension orders for drug licenses of stores located in Karnataka. The suspension is for one day for stores in Gajendragad and Collegr Road, Gadag. This action was taken by the Assistant Director, Drugs Control Administration, Circle Gadag, Karnataka, under the Drugs and Cosmetics Act, 1940 and Rules, 1945. The company estimates a potential revenue loss of ₹0.32 lacs and ₹0.47 lacs from these two stores due to the suspension. The details will be available on the company's website and stock exchange websites.

Medplus Health Services Ltd announced that its subsidiary, Optival Health Solutions Private Limited, has received three suspension orders for drug licenses of stores located in Karnataka and Andhra Pradesh. The suspensions are for one day in Hubli, Karnataka; two days in Gadag, Karnataka; and three days in Attapur, Andhra Pradesh. These actions were taken by the Drugs Control Administration authorities. The company estimates a potential revenue loss of ₹0.22 lacs from the Hubli store, ₹0.60 lacs from the Gadag store, and ₹0.76 lacs from the Attapur store, totaling ₹1.58 lacs. The company has stated that this information will be available on its website and the stock exchanges.

Medplus Health Services Ltd announced that its subsidiary, Optival Health Solutions Private Limited, has received a suspension order for a Drug License for a store located in Chikkamagaluru, Karnataka. The suspension is for a single day, effective from June 24, 2026. This action was taken under Rule 65 of the Drugs and Cosmetics Act, 1940 and Rules, 1945. The company estimates a potential revenue loss of approximately ₹0.46 lacs due to this temporary suspension. The details of the order will be available on the company's website and stock exchange websites.

Medplus Health Services Ltd has announced the closure of its trading window for all designated persons, including their immediate relatives, effective July 01, 2026. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will remain shut until 48 hours after the declaration of the un-audited financial results for the quarter ended June 30, 2026. The specific date for the board meeting to consider these financial results will be communicated in due course and will be available on the company's website and stock exchange websites.

Medplus Health Services Ltd announced that its subsidiary, Optival Health Solutions Private Limited, has received two suspension orders for drug licenses of stores located in Andhra Pradesh. The suspensions are for seven days each, affecting stores in East Godavari and Kurnool & Nandyal districts. The company cited violations under the Drugs and Cosmetics Act, 1940 and Rules, 1945. The potential revenue loss is estimated at ₹1.92 lacs for one store and ₹1.00 lac for the other. The details of these orders will be available on the company's website and stock exchanges.

Medplus Health Services Ltd announced that its subsidiary, Optival Health Solutions Private Limited, has received a suspension order for a drug license for a store located in Maharashtra. The suspension is for a period of 10 days, effective from June 20, 2026. This action was taken by the Asst. Commissioner & Licensing authority, Food & Drug Administration, MH, Pune, citing violations under the Drugs and Cosmetics Act, 1940 and Rules, 1945. The company estimates a potential revenue loss of ₹2.68 lacs due to this suspension. The details of the order will be available on the company's website and stock exchange websites.